What is the standard dosing protocol for TB-500?

Conventional TB-500 dosing is 2-5 mg 1-2x weekly subq (loading phase); maintenance lower via subq/im. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

How do I schedule TB-500 alongside my existing stack?

TB-500's schedule is built around its ~2-3 days pharmacokinetics and 1-2x weekly subq (loading phase); maintenance lower dosing pattern. Coordination with other peptides depends on route compatibility (multiple SubQ compounds can share an injection where chemistry permits), receptor overlap (avoid stacking compounds engaging the same primary receptor), and operational convenience. Add one new compound at a time with 2 weeks of isolated dosing before stacking.

What is the evidence base for TB-500?

TB-500's evidence base sits at preclinical + veterinary clinical (equine). The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The protocol / scheduling / cycling interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Is TB-500 safe during pregnancy or breastfeeding?

TB-500, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Home/ Compounds/ TB-500

TB-500

Protocol

Protocol design for TB-500 starts with pharmacokinetics and ends with calendar planning. The compound's ~2-3 days half-life via subq/im administration places it in the weekly-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.

Protocol / Scheduling / Cycling Applications

Stack SchedulingMulti-Peptide TimingProtocol CalendarPeriodised CyclesWash-Out

Key Takeaways

Scheduling lens: TB-500's ~2-3 days half-life via subq/im places it in the weekly-dosing bucket.
Mechanism: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, Ipamorelin, CJC-1295 without DAC (Mod GRF 1-29).

Protocol / Scheduling / Cycling Mechanism

Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. This influences cell migration during repair, angiogenesis, and stem-cell mobilisation. Acts systemically when injected anywhere, unlike many peptides whose effects are local. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for TB-500.

Cycle length and off-cycle planning

Standard TB-500 cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any TB-500 protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most TB-500 schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Stack scheduling with other compounds

When TB-500 is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.

Protocol / Scheduling / Cycling Applications

Stack Scheduling

The most-asked scheduling question for TB-500 in stack scheduling is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Periodised Cycles

Schedule design for TB-500 in periodised cycles starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Off-Time

For off-time scheduling, TB-500 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Cycle Design

The most-asked scheduling question for TB-500 in cycle design is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	2-5 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-5 mg	4–6 weeks initial cycle
Protocol focus	SubQ	2-5 mg	1-2x weekly SubQ (loading phase); maintenance lower
Maintenance phase	SubQ	1-5 mg	Ongoing with periodic pauses

Dose timing for TB-500 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

TB-500 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

TB-500 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with TB-500's mechanism in protocol / scheduling / cycling protocols.
TB-500 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with TB-500's mechanism in protocol / scheduling / cycling protocols.
TB-500 + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with TB-500's mechanism in protocol / scheduling / cycling protocols.
TB-500 + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with TB-500's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Banned (S0) FDA: Unapproved Research: Preclinical + veterinary clinical (equine)

Generally well tolerated. Limited human safety data. Avoid in active cancer.

Lens-specific safety considerations for protocol / scheduling / cycling use of TB-500: Generally well tolerated. Limited human safety data. Avoid in active cancer. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Thymosin β4 and tissue regeneration

PMID 19737543

Supporting

Thymosin β4 — actin sequestration and repair

PMID 22515427

TB-500 vs Related Peptides

Compound	Profile	Onset	Best For
TB-500	Synthetic thymosin β4 fragment	~2-3 days	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Daily timing for TB-500?

Pragmatic timing depends on pharmacokinetics: single weekly dose for long half-life. Consistent timing matters more than the absolute clock time of any single dose.

Cycle length and off-cycle period?

Standard cycle for TB-500 is 8–12 weeks on, 4 weeks off. Longer cycles produce diminishing returns and increased downregulation risk; shorter cycles undershoot the response window. The 4-week off-period is functionally required for receptor reset rather than optional.

What is the regulatory status of TB-500?

TB-500 regulatory status: Unapproved in the United States; WADA status banned (s0); research level preclinical + veterinary clinical (equine). Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What should I look for in TB-500 sourcing and quality?

Acceptable TB-500 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 888-1717 Da (depending on form), endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Clinical Protocol

Start a TB-500 Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified TB-500 and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 888-1717 Da (depending on form)
Sequence length: 17 aa
Half-life: ~2-3 days
WADA: Banned (S0)
FDA: Unapproved
Research: Preclinical + veterinary clinical (equine)

Stack Partners

BPC-157

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for TB-500 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for TB-500

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised